



08-11-05

Dfw

Dkt. No. 29248/21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Erik Buntinx  
Appl. No. : 10/803,793  
Filed : March 18, 2004  
For : METHOD OF TREATING NEURODEGENERATIVE  
DISEASES USING D4 AND 5-HT2A ANTAGONISTS, INVERSE  
AGONISTS OR PARTIAL AGONISTS  
Group Art : 1617  
Examiner : Gregory W. Mitchell  
Customer No. : 1912

"Express Mail" mailing label No.	EV 725786145 US
Date of Deposit:	August 10, 2005
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Alan D. Phillips
Signature:	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the references that are listed on Form PTO/SB/08A-B (6 pages) attached hereto. All of these references were cited in European Search Reports issued in connection with related European Patent Application Nos. EP 03 44 7279.5, EP 04 44 7066.4, and/or EP 04 02 5035.9, and/or in an International Search Report issued in connection with related PCT Patent Application No. PCT/BE2004/000172. Copies of the non U.S. patent publication references listed on the attached forms and of the Search Reports have been submitted to the U.S. Patent Office in connection to U.S. Patent Applications Nos. 10/725,965 and 10/752,423, from

Applicants: Erik Buntinx  
Appl'n. No.:10/803,793  
Filed: March 18, 2004  
Page 2


which the subject application claims the benefit of an earlier effective filing date under 35 U.S.C. §120. Accordingly, pursuant to 37 C.F.R. §1.98(d), copies of the aforementioned references and Search Reports are not included with this Information Disclosure Statement.

Finally, it is also brought to the Examiner's attention the existence of applicant's later-filed U.S. Patent Application No. 10/984,683, which claims priority of and is a continuation-in-part of the subject application. U.S. Patent Application No. 10/984,683 has not yet published.


Applicants are submitting the subject Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required in connection with the submission of this Information Disclosure Statement or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,  
AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

By

  
Alan D. Miller, Reg. No. 42,889

Dated: August 10, 2005  
New York, New York



16 10 2003

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

Approved for use through 07/01/2006. GPO 0001-000

information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

**(Use as many sheets as necessary)**

Shee

1

1

Complete if Known

**Complete if Known**

Application Number	10/803,793
Filing Date	March 18, 2004
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Gregory W. Mitchell
Attorney Docket Number	29248/21

U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	4	WO 01/98298 A	12-27-2001	H. LUNDBECK A/S		
	5	WO 98/43646 A	10-08-1998	AKZO NOBEL N.V.		
	6	WO 98/11897 A	03-26-1998	ELI LILLY AND COMPANY		
	7	WO 00/64441 A	11-02-2000	RESPIRATORIUS AB		
	8	WO 02/051833 A	07-04-2002	E.C.L.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.*

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.			
<b>Complete if Known</b>			
Substitute for form 1449/PTO		Application Number	10/803,793
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Filing Date	March 18, 2004
		First Named Inventor	Erik Buntinx
		Art Unit	1617
		Examiner Name	Gregory W. Mitchell
Sheet	2	of	6
		Attorney Docket Number	29248/21

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 2 of 6

## **U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	9	DE 40 39 631 A	06-17-1992	Troponwerke GmbH &	
				Co KG	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,793
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	Erik Buntinx
				<b>Art Unit</b>	1617
				<b>Examiner Name</b>	Gregory W. Mitchell
Sheet	3	of	6	Attorney Docket Number	29248/21

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	10	SCHINDLER T et al., entitled "Palliative medical management in anxiety and depression," Zeitschrift Fur Allgemeinmedizin, Vol. 74, No. 21, November 5, 1998, pp. 973-978.			
	11	VOLMAT R et al., entitled "The treatment of depressions by Cledial. Evolution and clinical state and handwriting," Psychologie Medicale, Vol. 18, No. 10, 1986, pp. 1615-1622.			
	12	FOUKS et al., entitled "Treatment of character disorders with a new butyrophenone: R. 3345 or pipamperone," Annales Medico-Psychologiques, Vol. 124, No. 5, 1966, pp. 677-681.			
	13	SQUELART P et al., entitled "Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients," Acta Psychiatrica Belgica, Vol. 77, No. 2, March 1977, pp. 284-293.			
	14	KOCH H J et al., entitled "Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride," International Journal of Clinical Practice, Vol. 57, No. 2, March 2003, pp. 147-149.			
	15	DIEBOLD K et al., entitled "Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?" Pharmacopsychiatry, 1998, 31/2, pp. 60-67.			
	16	GROZINGER M et al., entitled "Melperone is an inhibitor of the CYP2D6 catalyzed 0-demethylation of venlafaxine," Pharmacopsychiatry, Vol. 36, No. 1, January 2003, pp. 3-6.			
	17	PERUGI G et al., entitled "Effectiveness of Adjunctive Gabapentin in Resistant Bipolar Disorder: Is it due to anxious-alcohol abuse comorbidity?" Journal of Clinical Psychopharmacology, Vol. 22, No. 6, 2002, pp. 584-591.			
	18	WIELING W et al., entitled "Initial orthostatic hypotension as a cause of recurrent syncope: A case report," Clinical Autonomic Research, Vol. 11, No. 4, 2001, pp. 269-270.			
	19	DATABASE PHARMAPROJECTS 'ONLINE! PJB Publications Ltd., December 1999. Caesar accession no. 1498			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,793
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	Erik Buntinx
				<b>Art Unit</b>	1617
				<b>Examiner Name</b>	Gregory W. Mitchell
Sheet	4	of	6	<b>Attorney Docket Number</b>	29248/21

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	20	ADLER L et al., entitled "Praxis Der Stationaeren Akutbehandlung Von Manien Retrospektive Vergleichsuntersuchung An Je 100 Patienten Zweier Psychiatrischer Sentren Practice of In-Patient Acute Treatment of Manias," <i>Fortschritte Der Neurologie Psychiatrie</i> , Stuttgart, Vol. 62, No. 12, 1994, pp. 479-488.		
	21	ANSOMS C et al., entitled "Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamerone (Dipiperon)," <i>Acta Psychiatrica Scandinavica</i> , Vol. 55, No. 2, February 1977, pp. 116-122.		
	22	LEYSEN J E et al., entitled "Receptor interactions of new antipsychotics: Relation to Pharmacodynamic and Clinical Effects," <i>International Journal of Psychiatry in Clinical Practice</i> , Vol. 2, No. 1, 1998, pp. S03-S17.		
	23	VANHOENACKER P et al., entitled "Efficient Expression of the Human Dopamine D4.2 Receptor: Positive Influence of Pipamperone on Expression Levels," <i>Abstracts of the Society for Neuroscience</i> , Vol. 26, No. 1/2, 2000.		
	24	SCHOTTE A et al., entitled "Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding," <i>Psychopharmacology</i> , Vol. 124, No. 1-2, 1996, pp. 57-73.		
	25	WOGGON B, entitled "Pharmakologische depressionbehandlung pharmacological treatment of depression," <i>Therapeutische Umschau</i> , Vol. 57, No. 2, 2000, pp. 81-89.		
	26	VAN DE VIJVER DAMC et al., entitled "Antipsychotics and Parkinson's disease: Association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment," <i>Eur J Clin Pharmacology</i> , Vol 58, 2002, pp. 157-161.		
	27	JOVIC NI et al., entitled "Phenomenology and treatment of delirium in Alzheimer's disease!" <i>Revue Medicale De La Suisse Romande</i> , Vol. 117, No. 9, September 1997, pp. 655-658.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,793
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	Erik Buntinx
				<b>Art Unit</b>	1617
				<b>Examiner Name</b>	Gregory W. Mitchell
Sheet	5	of	6	Attorney Docket Number	29248/21

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	28	ENGELBORGH S et al., entitled "Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease," Neurochemical Research, Vol. 28, No. 8, August 2003, pp. 1145-1150.			
	29	NEWMAN-TANCREDIT A et al., [35S]-guanosine-5'-0-(3-thio) triphosphate binding as a measure of efficacy at human recombinant dopamine D-4.4 receptors: Actions of antiparkinsonian and antipsychotic agents. Journal of Pharmacology and Experimental Therapeutics, Vol. 282, No. 1, 1997 pp. 181-191.			
	30	TARAZI F I et al., entitled "Role of dopamine D4 receptors in neuropsychiatric disorders," Journal of Neurochemistry, Vol. 81, No. Supplement 1, June 2002, p. 33. Abstract			
	31	TARAZI F I et al., entitled "Dopamine D4 Receptors: Significance for Molecular Psychiatry at the Millennium," Molecular Psychiatry, Vol. 4, No. 6, November 1999, pp. 529-538.			
	32	LEOPOLD N A, entitled "Risperidone treatment of drug-related psychosis in patients with parkinsonism," Movement Disorders. Vol. 15, No. 2, March 2000, pp. 301-304.			
	33	HADJ TAHAR A et al., entitled "Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys," European Journal of Pharmacology, Vol. 399, No. 2-3, July 7, 2000, pp. 183-186.			
	34	ZESIEWICZ TA et al., entitled "Clozapine withdrawal symptoms in a Parkinson's disease patient," Movement Disorders: Vol. 17, No. 6, November 2002, pp. 1365-1367.			
	35	FALTRACO F et al., Akuelle Therapiemoglichkeiten der Alzheimer Demenz (Current Therapeutical Strategies in Dementia), Neurol Rehabil 2003; 9 (1), pp.15-22.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/803,793
				Filing Date	March 18, 2004
				First Named Inventor	Erik Buntinx
				Art Unit	1617
				Examiner Name	Gregory W. Mitchell
Sheet	6	of	6	Attorney Docket Number	29248/21

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	36	ETCHEPAREBORDA M C, entitled "Neurocognitive and pharmacological approach to specific learning disorders," Database Medline "Online!, US National Library of Medicine, February 1999, and Revista De Neurologia, Vol. 28, Suppl. 2, February 1999, pp. S81-S93, Abstract.			
	37	STAHL S M et al., entitled "Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease," Current Medical Research and Opinion 2004, Vol. 20, No. 4, 2004, pp. 517-524.			
	38	MENESES A et al., entitled "Are 5-HT (1B/1D) and 5-HT (2A/2B/2C) receptors involved in learning and memory processes?" IDrugs 1999, Vol. 2, No. 8, 1999, pp. 796-801.			
	39	WIRZ-JUSTICE A et al., entitled "Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease," Alzheimer Disease and Associated Disorders, Vol. 14, No. 4, 2000, pp. 212-215.			
	40	FAHS H et al., entitled "Thymoregulateurs Dans L'Agitation et les Troubles Du Comportement Chez le Sujet Dement a Propos de Huit Cas, Anticonvulsivants and Aggresive Behaviors in Alzheimer's Disease. Eight Cases Reports," L'Encephale			
		Vol. 25, No. 2, 1999, pp. 169-174.			
	41	WERTH E et al., entitled "Decline in long-term circadian rest-activity cycle organization in a patient with dementia," Journal of Geriatric Psychiatry and Neurology, Vol. 15, No. 1, April 2002, pp. 55-59.			
	42	MELTZER HY et al., entitled "Plasma clozapine levels and the treatment of L-Dopa-induced psychosis in Parkinson's disease. A high potency effect of clozapine," Neuropsychopharmacology, Vol. 12, No. 1, 1995, pp. 39-45.			
	43	MUNCHAU A et al., entitled "Pharmacological Treatment of Parkinson's Disease," Postgraduate Medical Journal, Vol. 76, October 2000, pp. 602-610.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.